Icodextrin - Generic Drug Details

What are the generic sources for icodextrin and what is the scope of patent protection?

Icodextrin is the generic ingredient in one branded drug marketed by Vantive Us Hlthcare and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for icodextrin. One supplier is listed for this compound.

Summary for icodextrin

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	23
Clinical Trials:	22
DailyMed Link:	icodextrin at DailyMed

Recent Clinical Trials for icodextrin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Children's Hospital of Fudan University	NA
The UCL Great Ormond Street Institute of Child Health	NA
Philippine Children's Medical Center	NA

See all icodextrin clinical trials

Pharmacology for icodextrin

Drug Class	Blood Coagulation Factor Calculi Dissolution Agent Osmotic Laxative Phosphate Binder
Mechanism of Action	Magnesium Ion Exchange Activity Osmotic Activity Phosphate Chelating Activity
Physiological Effect	Increased Coagulation Factor Activity Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Inhibition Small Intestine Fluid/Electrolyte Absorption Stimulation Large Intestine Fluid/Electrolyte Secretion

US Patents and Regulatory Information for icodextrin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321-001	Dec 20, 2002		RX	Yes	Yes

Expired US Patents for icodextrin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321-001	Dec 20, 2002
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321-001	Dec 20, 2002
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321-001	Dec 20, 2002
Vantive Us Hlthcare	EXTRANEAL	icodextrin	SOLUTION;INTRAPERITONEAL	021321-001	Dec 20, 2002

Icodextrin Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Icodextrin?

Icodextrin is a glucose polymer primarily used as an osmotic agent in peritoneal dialysis (PD). It has gained traction in nephrology due to its longer-lasting osmotic efficacy compared to dextrose-based solutions. The global market for icodextrin is influenced by demographic trends, regulatory policies, and technological advances in dialysis treatment.

Market Drivers

• Rising Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) Incidence: The increasing prevalence of CKD and ESRD acts as the primary demand driver. The United States Renal Data System (USRDS) reports approximately 786,000 patients undergoing dialysis in 2021, a figure expected to grow annually.
• Shift Towards Peritoneal Dialysis: Healthcare systems favor PD for its cost-effectiveness, patient convenience, and lower infection risk relative to hemodialysis. The International Society for Peritoneal Dialysis (ISPD) notes PD usage increased by 5% annually from 2015-2020.
• Preference for Biocompatible Dialysis Solutions: Icodextrin offers a biocompatible alternative to dextrose solutions, reducing peritonitis risk and preserving residual renal function. This competitive advantage sustains demand.

Market Challenges

• Pricing and Reimbursement Policies: Variations in third-party payer coverage influence market penetration. In the US, Medicare covers PD solutions, but recent policies favor dextrose options, restricting icodextrin use.
• Side Effects and Contraindications: Limited by potential hypersensitivity reactions and contraindications in certain patient populations, which may hinder widespread adoption.
• Manufacturing Constraints and Costs: Icodextrin production involves specialized enzymatic processes, which can impact supply and pricing. Supplier concentration for key manufacturers, e.g., Baxter and Fresenius Medical Care, raises supply chain risks.

Competitive Landscape

• Baxter International dominates the market with its product Extraneal, accounting for approximately 60-70% of global sales as of 2022. Fresenius Medical Care also markets icodextrin solutions, primarily in Europe.
• Research into alternative osmotic agents and modifications to existing formulations aims to enhance efficacy and reduce side effects.

How Is the Financial Trajectory of Icodextrin Evolving?

Revenue Trends

• The global market for icodextrin was valued at approximately $250 million in 2020. It is projected to reach around $430 million by 2027, with a compound annual growth rate (CAGR) of 7.5% (Research and Markets, 2021).
• North American sales represent roughly 40% of the market, driven by high ESRD prevalence and advanced healthcare infrastructure.
• Europe accounts for 35%, where regulatory approvals for icodextrin are mature and usage is integrated into standard PD protocols.

Revenue Sources

• Direct sales through pharmaceutical companies: Baxter's Extraneal generates revenue through direct-to-clinician and hospital sales.
• Distribution agreements: Companies partner with regional distributors, affecting profit margins and sales volume.
• Reimbursement policies: Reimbursements influence patient access, with countries like Japan providing favorable coverage, supporting higher adoption rates.

Investment and R&D Impact

• Research investments focus on optimizing formulation, reducing side effects, and expanding into new indications such as peritoneal membrane preservation.
• Regulatory filings in emerging markets, including China and South Korea, aim to broaden sales channels and increase revenue.

Market Risks Affecting Financial Outcomes

• Pricing pressures in mature markets due to hospital procurement negotiations.
• Patent expiries and generic competition could lead to downward pressure on prices.
• Technological shifts, such as the development of bioartificial kidneys or alternative dialysis modalities, threaten long-term demand.

What Are the Regulatory and Policy Trends Impacting the Market?

• The US Food and Drug Administration (FDA) approved the use of icodextrin in 1997. More recent updates include guidance on side effect management and labeling for pediatric use.
• European Medicines Agency (EMA) approvals date back to the early 2000s, with regulations focused on safety and efficacy.
• Countries like China have expedited approval pathways for renal medications, enabling quicker market entry, but local manufacturing quality standards vary, affecting importability and sales.

Key Market Players and Their Financial Positions

Company	Product	Market Share	Revenue (2022)	R&D Investment (2022)	Notable Strategies
Baxter International	Extraneal	60-70%	$11.2 billion*	$1.2 billion*	Expansion into emerging markets, formulation improvements
Fresenius Medical Care	Ferric and Icodextrin solutions	20-25%	€18.9 billion (2022)	€1.4 billion (2022)	Diversification into novel dialysis therapies
Other Generics/Depot Suppliers	Various	<10%	Data not specified	Data not specified	Focus on cost reduction and localized manufacturing

*Baxter’s global revenue, including dialysis products (Source: Baxter Annual Reports 2022).

Key Takeaways

• The growing ESRD population and preference for PD support sustained demand for icodextrin.
• Pricing pressures, regulatory policies, and side effect profiles pose ongoing challenges.
• Baxter leads market share, benefitting from established distribution and R&D investments.
• Revenue growth is driven by regional expansion, especially in emerging markets.
• Long-term market viability depends on formulation improvements, regulatory clearance, and technological innovations.

FAQs

1. What are the primary clinical advantages of icodextrin over dextrose-based solutions?
Icodextrin provides a sustained osmotic gradient, reducing ultrafiltration failure and preserving residual renal function. Its biocompatibility diminishes peritoneal membrane damage and lowers infection risk.

2. Which regions are expected to see the fastest growth in icodextrin demand?
Emerging markets in Asia, such as China and India, are projected to see rapid growth due to increasing CKD prevalence, expanding healthcare infrastructure, and regulatory approvals.

3. How does patent status affect the availability of generic icodextrin products?
While the original patents for Baxter’s Extraneal expired in multiple jurisdictions around 2017-2020, manufacturing barriers and regulatory hurdles limit proliferation of generics, maintaining Baxter’s market dominance.

4. What technological developments could threaten the growth of icodextrin?
Advances in bioartificial kidneys and alternative dialysis techniques could reduce reliance on peritoneal dialysis solutions, including icodextrin.

5. How do reimbursement policies impact icodextrin sales?
In countries with favorable reimbursement policies (e.g., Japan), sales are high. Conversely, policies favoring cheaper dextrose solutions or limited coverage can restrict sales volumes.

References

[1] USRDS Annual Data Report 2021
[2] Research and Markets, "Global Icodextrin Market Analysis," 2021
[3] Baxter Annual Report 2022
[4] ISPD Peritoneal Dialysis Trends, 2020
[5] FDA and EMA drug approval databases